Compendium

Gene and RNA Therapeutics — Deep Reference

23 min read

Gene and RNA Therapeutics — Deep Reference

A Tier 2 deep-dive into the platforms that deliver genetic information as therapy: AAV / lentivirus / adenovirus vectors, in vivo and ex vivo CRISPR + base editors + prime editors, mRNA-LNP, antisense oligonucleotides, siRNA, saRNA / circular / STAR RNA, RNA editing (ADAR-guided), and the manufacturing + cost-of-goods economics that frame whether a $2-3M one-time cure is a sustainable business. The watershed was the FDA approval of Luxturna (AAV2 voretigene neparvovec) on 19 Dec 2017 — the first directly-administered gene therapy in the US, for RPE65-mutation Leber congenital amaurosis at $425k/eye. By 2026 the field counts 12+ FDA-approved gene/cell therapies including Casgevy and Lyfgenia (sickle cell disease, both Dec 2023), Hemgenix (hemophilia B, $3.5M), Elevidys (DMD, $3.2M), and Skysona (CALD, $3M); 10+ approved siRNAs and ASOs including Leqvio, Onpattro, Spinraza, Vyondys, Casimersen, Qalsody, Wainua; the 2020 COVID mRNA vaccine validation has now spawned mRNA cancer vaccines (BioNTech BNT113, Moderna mRNA-4157) and metabolic-disease mRNA replacement (Moderna mRNA-3705 for GSD1a, mRNA-3927 for PA). This note covers the viral capsid + LNP delivery chemistry, the genomic editing tool palette, clinical pipeline by mechanism, and the pricing controversies that increasingly drive policy.

See also

AAV (adeno-associated virus) delivery

Single-stranded ~4.7 kb DNA virus; ~25 nm icosahedral capsid; ssDNA genome with inverted terminal repeats (ITRs); non-pathogenic in humans (wild-type AAV-2 produces no disease); requires helper virus (adenovirus, herpes) for replication — engineered as replication-defective vector by removing rep + cap genes from cargo plasmid.

Natural serotypes and tropism

  • AAV1. Muscle (intramuscular).
  • AAV2. Original; broad CNS, retina, liver; used in Luxturna.
  • AAV3. Hepatocytes (poor in humans without engineering).
  • AAV4, AAV5. RPE, CNS, lung; AAV5 in Hemgenix.
  • AAV6. Muscle, lung, lymphoid.
  • AAV7, AAV8. Liver — AAV8 strong liver tropism, used in Hemgenix Phase 3 lead-in studies and Roctavian (valoctocogene roxaparvovec; BioMarin; FDA 29 June 2023 for hemophilia A).
  • AAV9. Crosses BBB; CNS + cardiac + skeletal muscle. Used in Zolgensma (onasemnogene abeparvovec; Novartis; FDA 24 May 2019 for SMA at $2.125M/dose) and Elevidys (delandistrogene moxeparvovec; Sarepta; FDA 22 June 2023 for DMD at $3.2M/dose).
  • AAV-rh10. Rhesus-derived; non-cross-reactive with human pre-existing immunity.

Capsid engineering

Pre-existing neutralizing antibodies (NAbs) against AAV2/8/9 in ~30-70% of human population block re-dosing and exclude some patients. Capsid engineering aims to evade NAbs, enhance tropism, reduce off-target.

  • DNA shuffling + directed evolution (Schaffer-Bhattacharya UC Berkeley). Capsid library + selection in vivo or on tissue → improved variants. AAV-DJ (Grimm-Kay 2008), AAV2.7m8 (Dalkara-Schaffer 2013 — retinal). 4D Molecular Therapeutics, Adverum.
  • AAV-PHP.B / AAV-PHP.eB (Deverman-Gradinaru Caltech 2016). Engineered AAV9 capsids that cross BBB ~40× more efficiently in C57BL/6 mice via Ly6a binding; human translation limited because Ly6a is mouse-specific. AAV.CAP-B10 / CAP-B22 (Goeden-Gradinaru 2022) cross BBB in primate.
  • DELIVER, Dyno BIO platform. Dyno Therapeutics — ML-guided capsid design (Bhattacharya-Sinai 2023 Nature Methods) — VAEs trained on selection data predict capsid sequences with desired tropism + immune evasion. Partnerships with Roche, Novartis, Sarepta.
  • AAVantage, REGENXBIO NAV. Different proprietary capsid families.
  • Lefkonopoulou-Schaffer 2024. Most recent capsid evolution paper using ML.

Production

  • HEK293 transient triple-transfection. AAV vector plasmid + Rep/Cap plasmid + helper plasmid (Ad5 helper genes — VA, E2A, E4) → 72 h → harvest → iodixanol gradient or affinity chromatography (AVB Sepharose, POROS CaptureSelect AAV) + ion-exchange polish.
  • Sf9 insect cells + baculovirus. OneBac, ScaleReady Mycroft. Scalable to 200-2000 L bioreactor.
  • Producer cell lines. Inducible Rep/Cap-integrated cell lines; emerging.

Yield: ~1-5 × 10¹³ vg/L (vector genomes per liter); per-dose 1 × 10¹⁴ vg (Zolgensma) = 20-100 L culture per dose.

Cost of goods

Estimates for AAV at clinical scale: $50-300k/dose COGS for high-dose products (Zolgensma, Hemgenix), $20-80k for ocular/local-delivery low-dose products (Luxturna). Drives the $2-3M list price floor; payer pushback is mounting (CMS Cell and Gene Therapy Access Model 2025).

Approved AAV therapies

  • Luxturna (voretigene neparvovec; Spark Therapeutics → Roche). FDA 19 Dec 2017. AAV2-RPE65 for RPE65-mutation LCA. Subretinal injection; $850k/patient ($425k/eye).
  • Zolgensma (onasemnogene abeparvovec; AveXis → Novartis). FDA 24 May 2019. AAV9-SMN1 for SMA. IV; $2.125M.
  • Hemgenix (etranacogene dezaparvovec; CSL Behring / uniQure). FDA 22 Nov 2022. AAV5-FIX-Padua for hemophilia B. IV; $3.5M.
  • Roctavian (valoctocogene roxaparvovec; BioMarin). FDA 29 June 2023. AAV5-FVIII-SQ for hemophilia A. IV; $2.9M.
  • Elevidys (delandistrogene moxeparvovec; Sarepta). FDA 22 June 2023 (accelerated, expanded 2024 to broader DMD population). AAV-rh74-micro-dystrophin. IV; $3.2M.
  • Beqvez (fidanacogene elaparvovec; Pfizer). FDA 25 Apr 2024. AAV-Spark100 for hemophilia B. IV; $3.5M.

Lentivirus and retrovirus

Integrating retroviruses based on HIV-1 (lentivirus) or MLV (γ-retrovirus). Pack 8-10 kb cargo; transduce dividing + non-dividing cells (lentivirus only); integrate semi-randomly into host chromosome.

Generations of lentiviral vector

  • 1st gen. Wild-type HIV gag-pol-env genes; risk of replication-competent lentivirus (RCL).
  • 2nd gen. Split: gag-pol on packaging plasmid; tat-rev separate; env (VSV-G typically); transfer vector.
  • 3rd gen. Tat removed (replaced with constitutive promoter for transfer-vector RNA); rev kept on separate plasmid; self-inactivating (SIL) transfer vector with deleted 3’LTR U3 → integrated provirus cannot transcribe full-length RNA.
  • 4th gen / next-gen. Codon-optimized, integration-deficient (IDLV — Class I integrase mutations) variants for transient expression; targeted-integration (CRISPR-Cas9 + HDR donor on lentivirus).

Approved + clinical lentivirus therapies

  • Strimvelis (autologous CD34+ + γ-retrovirus-ADA; Orchard Therapeutics / GSK). EMA 26 May 2016. ADA-SCID. ~€594k.
  • Libmeldy (atidarsagene autotemcel; Orchard). EMA 17 Dec 2020 / FDA 18 Mar 2024 as Lenmeldy. Lentivirus-ARSA for metachromatic leukodystrophy. $4.25M (Lenmeldy 2024 list price — highest ever for a drug).
  • Skysona (elivaldogene autotemcel; bluebird bio). FDA 16 Sept 2022. Lentivirus-ABCD1 for cerebral adrenoleukodystrophy. $3M.
  • Lyfgenia (lovotibeglogene autotemcel; bluebird bio). FDA 8 Dec 2023. Lentivirus-βAS3 hemoglobin for sickle cell disease. $3.1M.
  • Zynteglo (betibeglogene autotemcel; bluebird bio). FDA 17 Aug 2022. Lentivirus-βA-T87Q for β-thalassemia. $2.8M.
  • Casgevy (exagamglogene autotemcel; Vertex / CRISPR Therapeutics). FDA 8 Dec 2023 — see CRISPR section. Note: Casgevy is CRISPR-edited, not lentivirus.

Lentivirus dominates ex vivo CD34+ HSC editing and CAR-T (see immunoengineering-and-cell-therapy).

Insertional mutagenesis safety

Early X-SCID γ-retroviral trials (1999-2003 Fischer-Cavazzana-Calvo) cured immunodeficiency but caused leukemia in 5/20 patients due to LMO2 insertional activation. 3rd-gen SIN lentivirus + integration profiling (LAM-PCR + LM-PCR + insertion site sequencing) has substantially reduced — but not eliminated — risk. The Nov 2023 FDA boxed warning on CAR-T (T-cell malignancies; ~30 cases) revived integration-mutagenesis concerns for lentiviral CAR-T.

Adenovirus

dsDNA virus; 26-45 kb capacity; high transduction efficiency in many cell types; strong T-cell + Ab immunity in human population (most adults sero-positive for Ad5).

Adenoviral vector generations

  • 1st gen. ΔE1, ΔE3. Strong immunogenicity; transient expression.
  • Helper-dependent (“gutless”). All viral genes removed; max insert ~36 kb; requires helper Ad5 for production then purification.

Clinical uses

  • Vaccines. Janssen Ad26.COV2.S (Ad26 vector COVID; FDA 27 Feb 2021 EUA → full approval pending); AstraZeneca/Oxford ChAdOx1 nCoV-19 (chimp Ad-Y25 vector); Sputnik V Ad26+Ad5; Ebola Ad26.ZEBOV (Janssen MVA-BN; FDA 1 July 2020); RSV Arexvy (GSK; Feb 2024).
  • Gene therapy. Limited approved use due to immunogenicity. China NMPA approved Gendicine (rAd-p53; Shenzhen SiBiono 2003) — first gene therapy approved anywhere; oncology intratumoral.
  • Oncolytic. Imlygic (talimogene laherparepvec; T-VEC; HSV-1 actually, not Ad; Amgen; FDA 27 Oct 2015) — first approved oncolytic; melanoma. ONYX-015 (Onyx-Calydon; ΔE1B); H101 (Chinese Gendicine analog).

In vivo CRISPR therapeutics

Delivering CRISPR machinery (Cas9 + sgRNA, or base/prime editor + guide RNA) directly into the body — typically by LNP-mRNA, AAV, or virus-like particle.

Approved / late-stage

  • Casgevy (exagamglogene autotemcel; exa-cel; Vertex + CRISPR Therapeutics). FDA 8 Dec 2023 for sickle cell disease, 16 Jan 2024 for β-thalassemia. Ex vivo CRISPR-Cas9 KO of BCL11A erythroid enhancer in autologous CD34+ HSCs → re-induces fetal hemoglobin (HbF). Manufacturing: apheresis → electroporation with Cas9 RNP + sgRNA → myeloablative busulfan conditioning → re-infusion. $2.2M list price; ~25 authorized treatment centers in US. First approved CRISPR therapy.
  • NTLA-2001 / nex-z (nexiguran ziclumeran; Intellia + Regeneron). In vivo LNP-Cas9 mRNA + sgRNA targeting TTR (transthyretin) for ATTR amyloidosis (HEAR-ATTR-CM Phase 3 NCT06672237 in progress; HEAR-ATTR Phase 3 NCT05819035). Phase 1 (NCT04601051) showed 90%+ serum TTR knockdown in single dose. Expected FDA filing 2025-2026.
  • NTLA-2002 (Intellia). In vivo LNP-Cas9 + sgRNA targeting KLKB1 for hereditary angioedema (HAE). Phase 3 (NCT06634420). Single dose eliminates attacks for >2 yr post-treatment.
  • VERVE-101, VERVE-102 (Verve Therapeutics; partnered with Lilly). In vivo LNP-base editor (ABE8.8 + sgRNA) targeting PCSK9 for heterozygous FH and atherosclerotic cardiovascular disease. VERVE-102 (improved targeting; GalNAc-LDLR-targeted LNP) — heart-1 NCT05398029 Phase 1b 2024 showed durable LDL reduction.
  • VERVE-201 (Verve). In vivo base editor targeting ANGPTL3 for refractory hypercholesterolemia / HoFH.
  • BEAM-101 (Beam Therapeutics). Ex vivo adenine base editing of HBG1/HBG2 promoter to upregulate HbF in autologous HSCs for sickle cell disease. Phase 1/2 (BEACON, NCT05456083).
  • BEAM-201 (Beam). Ex vivo CRISPR base editing CD7 + TRAC + PDCD1 + CD52 → allogeneic CD7-CAR T cell for T-ALL.
  • EDIT-301 / renizgamglogene autogedtemcel (reni-cel; Editas Medicine). Ex vivo Cas12a editing of HbF locus in autologous HSCs for sickle cell disease. RUBY trial NCT04853576. Editas BLA filing planned 2025.
  • EDIT-101 (Editas). In vivo subretinal AAV-Cas9 for CEP290-LCA10. First in vivo CRISPR trial (NCT03872479) 2020. Discontinued 2022 — insufficient efficacy.

CRISPR variants in clinic

  • SpCas9 (Streptococcus pyogenes Cas9). 4.1 kb; PAM 5’-NGG-3’. Most-used.
  • SaCas9 (Staphylococcus aureus). 3.2 kb; PAM 5’-NNGRRT-3’. Fits in AAV.
  • Cas12a (Cpf1; Acidaminococcus or Lachnospiraceae). PAM 5’-TTTV-3’. Smaller sgRNA. Used in EDIT-301.
  • CasX, CasY, Cas14. Smaller systems.
  • CasΦ (Cas12j). Phage-derived; minimal size.

Base editors (BE)

  • CBE (cytidine base editor). APOBEC1 / AID + nCas9 (D10A) + UGI → C·G → T·A. Komor-Liu 2016 Nature. BE3, BE4max, evoBE4max.
  • ABE (adenine base editor). Evolved TadA (Escherichia coli tRNA adenosine deaminase) + nCas9 → A·T → G·C. Gaudelli-Liu 2017 Nature. ABE7.10, ABE8.8, ABE8e (Richter-Liu 2020).
  • CGBE (C-to-G base editor). APOBEC + UDG → C·G → G·C transversion. Chen-Liu 2021 Nat Biotechnol.
  • TadA-derived CBE. Reduces RNA off-target.

Used in Verve (ABE8.8), Beam (ABE), and many academic programs.

Prime editors (PE)

Anzalone-Liu 2019 Nature. nCas9 + M-MLV reverse transcriptase + pegRNA (encodes target site + edit). PE2, PE3, PE3b, PEmax, PE5, twinPE, paired prime editing. All 12 base substitutions, small indels (~20 bp).

Prime Medicine PM359 (lead candidate, p47 chronic granulomatous disease ex vivo) entering clinic 2024.

Off-target characterization

  • GUIDE-seq, CIRCLE-seq, CHANGE-seq. Unbiased genome-wide off-target detection by capturing dsDNA breaks.
  • BLISS, DISCOVER-Seq. Variants.
  • CRISPResso2. Targeted amplicon NGS for on-target edit and known off-target site analysis.
  • EDISTO, off-target prediction in silico (Cas-OFFinder, CRISPOR).

Regulatory: FDA requires comprehensive off-target characterization with at least one unbiased method.

mRNA therapeutics

Approved mRNA products

  • Comirnaty (BNT162b2; Pfizer-BioNTech). FDA EUA 11 Dec 2020 → full approval 23 Aug 2021. COVID-19 vaccine. $130-200/dose.
  • Spikevax (mRNA-1273; Moderna). FDA EUA 18 Dec 2020 → full approval 31 Jan 2022. COVID-19 vaccine.
  • Both updated annually for variant matching (Omicron BA.5, XBB.1.5, JN.1, KP.2/KP.3).

Clinical mRNA pipeline beyond COVID

  • Moderna mRNA-3705 (GSD1a — glycogen storage disease type 1a). Phase 1/2 NCT05095727. mRNA-LNP encoding G6PC1. First successful mRNA enzyme replacement in clinic.
  • Moderna mRNA-3927 (propionic acidemia, PA). mRNA-LNP encoding PCCA + PCCB. NCT04159103 Phase 1/2 demonstrated clinical signal in 2023.
  • Moderna mRNA-3745 (MMA — methylmalonic acidemia). NCT06255782.
  • Moderna mRNA-3351 (CN-1 Crigler-Najjar). UGT1A1.
  • Moderna mRNA-4157 (individualized neoantigen cancer vaccine; partnered with Merck). Phase 3 INTerpath-001 (NCT05933577) melanoma; demonstrated 44% reduction in melanoma recurrence in combo with pembrolizumab (KEYNOTE-942 Phase 2b).
  • BioNTech BNT122 (autogene cevumeran). Phase 2 colorectal cancer + pancreatic.
  • BioNTech BNT113 (FixVac CMV-pp65 + tumor-associated). HPV16+ head-and-neck cancer. Phase 2 AHEAD-MERIT NCT04534205.
  • BioNTech BNT142 (CLDN6 × CD3 bispecific encoded as mRNA-LNP). In vivo mRNA-encoded TCE.
  • CureVac CV9202. NSCLC.
  • Arcturus LUNAR-COV19 (ARCT-154). Self-amplifying RNA (saRNA) COVID vaccine; approved Japan Nov 2023.

RNA chemistry advances

  • 5’cap. ARCA (anti-reverse cap analog) → cap-1 m7G(5’)ppp(5’)Nm pre-cap or co-transcriptional CleanCap (TriLink); enzymatic capping (vaccinia D1/D12).
  • Pseudouridine (Ψ) replacement. Karikó-Weissman 2005 Immunity — m1Ψ-modified mRNA evades TLR + RIG-I activation while preserving translation. Nobel Medicine 2023 to Karikó + Weissman. All approved mRNA therapeutics use m1Ψ.
  • Codon optimization. GC content, codon adaptation, RBS-equivalent 5’ UTR (alpha-globin, beta-globin 5’ UTRs).
  • PolyA tail. ~100-150 nt; templated PolyA or post-IVT enzymatic addition.

Self-amplifying RNA (saRNA)

Alphavirus replicase + cargo on single RNA; cargo amplifies inside cell → 100-fold lower dose. ~10 kb total. Replicate Bio, MiNA Therapeutics, Arcturus, Ziphius Vaccines, Pfizer (acquired Replicate’s pipeline partnership 2022).

Circular RNA / STAR / Repeat

  • circRNA. No free ends → resistant to exonucleases → ~10× longer half-life than linear mRNA. Orna Therapeutics (Whitehead-Mass) — oRNA platform. Laronde / Sail (acquired by Roche).
  • STAR (Self-Transcribing And Replicating RNA). Esperovax.
  • Replicon RNA (alphavirus-derived saRNA above).

Lipid nanoparticles (LNPs)

The delivery vehicle that made mRNA therapy clinically viable. Components:

  1. Ionizable cationic lipid. Protonated at endosomal pH (~5-6), neutral at physiological pH (~7.4) → endosomal escape via membrane fusion. Each company has proprietary lipids:
    • ALC-0315 (Acuitas, Pfizer-BioNTech licensee). In Comirnaty.
    • SM-102 (Moderna).
    • MC3 / DLin-MC3-DMA (Alnylam, Acuitas). First clinical ionizable lipid (Onpattro, 2018).
    • C12-200, KC2, cKK-E12. Older.
    • TRIM/2 ATX, Lipid 5, Lipid 12 (proprietary).
  2. Phospholipid (helper). DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) — bilayer structure.
  3. Cholesterol. Membrane integrity + fusogenicity.
  4. PEG-lipid. ~1-2 mol%; DMG-PEG2000, ALC-0159; surface stealth + colloid stability + manufacturing reproducibility.

Formulation

Microfluidic mixing (NanoAssemblr Ignite, Precision NanoSystems; T-junction mixers; Knauer Impingement Jet) — aqueous mRNA + ethanolic lipid mix → spontaneous nanoparticle assembly at neutral pH after buffer exchange. ~80-100 nm diameter; PDI <0.2; encapsulation efficiency >90%.

Tropism

Default LNP (IV): ApoE-mediated uptake → hepatocytes. ~70-90% of dose accumulates in liver.

Targeted LNPs

  • GalNAc-conjugated LNP (Verve VERVE-102). Tri-GalNAc on PEG-lipid; ASGPR-mediated hepatocyte uptake; enables lower dose.
  • CD5-targeted LNP (Tessera, Capstan, Rurik-Epstein 2022 Science).
  • PIP3 (lung-targeted). Charge-modulated lipids extend tropism to lung (Dahlman-Anderson 2020 Nat Nanotechnol — selective organ targeting, SORT).
  • Bone marrow-, spleen-targeted. SORT lipid variants.
  • Anti-CD8 / CD4 antibody-conjugated. In vivo CAR-T (Capstan / Tessera).

Antisense oligonucleotides (ASOs)

Short (15-25 nt) ssDNA / chemically modified RNA that hybridize to target RNA → RNase H1 cleavage (gapmer ASO with central DNA) or steric block (splice-switching oligo, SSO).

Chemistry generations

  • 1st gen. Phosphorothioate (PS) backbone; nuclease resistance, plasma protein binding.
  • 2nd gen. 2’-OMe, 2’-MOE (2’-methoxyethyl) sugar mods (Nusinersen, Mipomersen).
  • 3rd gen. LNA / BNA (locked nucleic acid, bridged nucleic acid); 2’-F, cET; constrained ethyl.
  • PMO (phosphorodiamidate morpholino). Sarepta exon-skipping platform; charge-neutral; cell entry by passive uptake.

Approved ASOs

  • Vitravene (fomivirsen; Ionis/Novartis). FDA 26 Aug 1998. First approved ASO. CMV retinitis. Withdrawn 2002 (HAART made it unnecessary).
  • Mipomersen (Kynamro; Ionis/Sanofi). FDA 29 Jan 2013. ApoB-100 for HoFH. Withdrawn 2019 (low uptake + hepatotoxicity).
  • Spinraza (nusinersen; Biogen/Ionis). FDA 23 Dec 2016. 2’-MOE PS ASO splice-switching SMN2 for SMA. $750k loading-year, $375k/yr maintenance.
  • Exondys 51 (eteplirsen; Sarepta). FDA 19 Sept 2016. PMO exon-51 skip for DMD.
  • Vyondys 53 (golodirsen; Sarepta). FDA 12 Dec 2019. Exon-53.
  • Viltepso (viltolarsen; NS Pharma). FDA 12 Aug 2020. Exon-53 (different chemistry).
  • Amondys 45 (casimersen; Sarepta). FDA 25 Feb 2021. Exon-45.
  • Tegsedi (inotersen; Ionis). FDA 5 Oct 2018. TTR for hATTR-PN. $300-450k/yr.
  • Waylivra (volanesorsen; Akcea/Ionis). EMA 7 May 2019 / FDA rejection. ApoC-III for FCS.
  • Qalsody (tofersen; Ionis/Biogen). FDA 25 Apr 2023. SOD1 for ALS-SOD1.
  • Wainua (eplontersen; Ionis/AstraZeneca). FDA 21 Dec 2023. TTR (GalNAc-conjugated; subcutaneous; weekly self-administered) — replacing Tegsedi.
  • Imetelstat (Rytelo; Geron). FDA 6 June 2024. Lipid-conjugated telomerase template-binding oligo for MDS. Distinct from gapmer/SSO ASOs but mechanistically related.

Delivery enhancement

  • GalNAc conjugation. Tri-antennary N-acetyl-galactosamine targets ASGPR on hepatocytes → 10-50× potency gain vs unconjugated. Standard for hepatocyte-targeted ASO + siRNA (Wainua, Leqvio).
  • Intrathecal delivery. Spinraza, Qalsody — direct CSF delivery for CNS targets.
  • Subcutaneous. Standard for systemic GalNAc-conjugated.
  • Intravitreal. Macular degeneration (Pegaptanib, withdrawn).

siRNA therapeutics

Double-stranded ~21-23 nt RNA → RISC complex (Argonaute-2) → mRNA degradation.

Approved siRNA

  • Onpattro (patisiran; Alnylam). FDA 10 Aug 2018. First siRNA approval. TTR for hATTR-PN. IV; ~$450k/yr.
  • Givlaari (givosiran; Alnylam). FDA 20 Nov 2019. ALAS1 for AHP (acute hepatic porphyria). SC GalNAc; $575k/yr.
  • Oxlumo (lumasiran; Alnylam). FDA 23 Nov 2020. HAO1 for PH1 (primary hyperoxaluria type 1). SC GalNAc; $493k/yr.
  • Leqvio (inclisiran; Novartis/Alnylam). FDA 22 Dec 2021. PCSK9 for hypercholesterolemia. SC GalNAc; ~$3,250/dose (2/yr); ~$6,500/yr — far cheaper than orphan-disease siRNAs.
  • Amvuttra (vutrisiran; Alnylam). FDA 13 June 2022. TTR for hATTR-PN (improved Onpattro — quarterly SC GalNAc instead of IV). HELIOS-B Phase 3 NCT04153149 expanded to ATTR-CM 2024.
  • Rivfloza (nedosiran; Novo Nordisk/Dicerna). FDA 29 Sept 2023. LDHA for PH1/2/3.
  • Fitusiran (ALN-AT3; Alnylam, partnered Sanofi). Phase 3 hemophilia A + B (ATLAS-A/B NCT03417245, NCT03417102). Antithrombin (SERPINC1) knockdown rebalances coagulation. FDA filing 2024.

siRNA chemistry

  • GalNAc conjugation (above).
  • 2’-OMe, 2’-F sugar modifications (alternating) → nuclease resistance + reduced off-target.
  • PS backbone at terminal nucleotides.
  • ESC (enhanced stabilization chemistry) — Alnylam proprietary architecture allowing quarterly or semiannual SC dosing.

RNA editing

ADAR-mediated A-to-I editing — guide RNA recruits endogenous ADAR1/2 to target adenosine → inosine substitution → read as G. Reversible (vs DNA editing); transient; no genomic risk.

Companies

  • Wave Life Sciences WVE-006 (AIMer ADAR-recruiting oligo). Phase 1b/2a (NCT05809869) for α-1 antitrypsin deficiency (AATD) — corrects M-to-Z mutation by recoding SNP.
  • Korro Bio. OPERA / OPRTV platform.
  • Beam Therapeutics K-EVO platform. Site-directed A-to-I editing.
  • ProQR Therapeutics. Sepofarsen Phase 3 LCA-CEP290 read-through; Phase 3 missed primary endpoint Mar 2022 — illustrates challenges.

Mechanism

Engineered guide oligonucleotide → forms dsRNA with target → ADAR endogenously recruits → deaminates target A → I → read as G in translation. Single-base correction without breaks. Transient → needs re-dosing — but also reversible if adverse.

Manufacturing

AAV manufacturing scale-up

  • Triple transfection HEK293F suspension. WAVE bioreactor (Cytiva) → 50-2000 L stirred-tank (Sartorius Biostat STR, Thermo HyPerforma). Yield ~10¹³-10¹⁴ vg/L; lot $5-50M.
  • Sf9 / baculovirus. OneBac, ReVec; insect cell scalability advantage.
  • Producer cell lines (Pall iCELLis, Vibalogics). Inducible Rep/Cap-integrated CHO/HEK293; emerging.
  • Continuous capture / polishing. AVB Sepharose (Cytiva), POROS CaptureSelect AAV (Thermo), Cimmultus (BIA Separations); ion-exchange polishing (POROS HQ, Capto Q).
  • Empty-full capsid separation. AUC (analytical ultracentrifugation), CDMS (charge-detection mass spec), CryoTEM particle counting. AEX achieves 60-90% full-capsid; remaining empty capsids dilute potency + add immunogenicity load.
  • Fill-finish. Single-dose vials; -80 °C or -20 °C storage; lyophilized formats in development.

mRNA manufacturing

  • IVT (in vitro transcription). Linearized DNA template (NotI, BsaI) + T7 RNA polymerase + NTPs + cap analog (CleanCap, ARCA, or enzymatic vaccinia capping post-IVT) → 4-8 h. Yield 2-10 mg/mL.
  • dsRNA removal. Cellulose chromatography (Karikó), oligo-dT, HPLC, tangential flow filtration.
  • DNase digest to remove template.
  • mRNA-LNP encapsulation. Microfluidic mixer at scale (NanoAssemblr Blaze, Precision NanoSystems; Knauer; Phyton).
  • Fill-finish. Vials -70 °C (BNT162b2 ULT) or -20 °C (mRNA-1273 — formulated for less harsh storage).

GMP mRNA cost-of-goods: ~$2-10/mg drug substance at scale; $0.5-5/dose for billion-dose pandemic-scale (Moderna, Pfizer disclosed COGS $1-3/dose).

LNP scale-up

Microfluidic mixing scales linearly — parallel devices (Precision NanoSystems Ignite NxGen 500). Manufacturing capacity bottleneck during COVID highlighted critical-supply-chain risk for ionizable lipid + PEG-lipid raw materials.

Cost-of-goods and pricing

List prices (US wholesale acquisition)

TherapyList priceMechanismIndication
Hemgenix$3.5MAAV5-FIX-PaduaHemophilia B
Roctavian$2.9MAAV5-FVIIIHemophilia A
Elevidys$3.2MAAV-rh74-microdystrophinDMD
Zolgensma$2.1MAAV9-SMN1SMA
Casgevy$2.2MEx vivo CRISPRSickle cell, β-thal
Lyfgenia$3.1MLentivirus-βAS3Sickle cell
Skysona$3.0MLentivirus-ABCD1CALD
Lenmeldy$4.25MLentivirus-ARSAMLD
Luxturna$0.85MAAV2-RPE65RPE65 LCA
Spinraza$0.75M loading, $0.375M/yrASOSMA
Leqvio$6.5k/yrsiRNAHypercholesterolemia

Outcome-based / installment contracts

  • Hemgenix / Roctavian. Outcome-based: 30-50% rebate if Factor IX/VIII level not maintained at 1+ year.
  • Zolgensma. AveXis/Novartis offered 5-year annuity option.
  • Spark / Roche Luxturna. Outcome warranty in some markets.

Payer access challenges

US Medicare/Medicaid coverage variability; many states impose prior-authorization, coverage limited to FDA-labeled indications, manufacturer rebates obscure list prices. CMS Cell and Gene Therapy Access Model (CGT; 2025) introduces voluntary multi-state Medicaid outcome-based contracts.

EU: UK NICE, German G-BA, French HAS conduct cost-effectiveness review. NICE rejected Libmeldy (2021) on cost-effectiveness; Orchard Therapeutics subsequently entered England managed-access agreement. NICE Innovative Medicines Fund.

Pricing controversies

  • Bluebird bio Zynteglo €1.8M EU launch (2019). Failed to gain payer access; bluebird withdrew Zynteglo from EU 2021; relaunched in US as bluebird’s Zynteglo + Skysona + Lyfgenia trio.
  • Hemgenix $3.5M. Pricing debate — payer claims long-term factor IX prophylaxis cost would otherwise exceed $3.5M over decades, justifying upfront price.
  • Casgevy $2.2M, Lyfgenia $3.1M. Sickle cell pricing; ICER fair-value estimate $2M (Casgevy) — list price close to ICER threshold; Lyfgenia exceeds.
  • Elevidys $3.2M. Sarepta DMD; accelerated approval 2023 controversial (limited efficacy data); 2024 expansion to broader DMD population despite mixed Phase 3 results.

Industry sustainability

Bluebird bio’s 2022 near-bankruptcy and Orchard’s Libmeldy launch challenges illustrate that approval ≠ commercial sustainability for rare-disease gene therapy. Buyout / consolidation trend: Orchard acquired by Kyowa Kirin (2023); BlueRock by Bayer; uniQure-CSL partnership.

Quality control and analytical characterization

AAV CQAs (critical quality attributes)

  • Titer. Vector genomes per mL by ddPCR (Bio-Rad QX200; targets ITR or transgene cassette) — orthogonal to total capsid count.
  • Capsid count. Total capsids by ELISA (Progen AAV ELISA kits) or charge-detection MS (CDMS — Megadalton CDMS in Heck lab, commercial via Megadalton Solutions).
  • Empty:full capsid ratio. AUC (Beckman Optima XL-I / XL-A analytical ultracentrifugation), CDMS, cryo-EM particle counting. Typical specification: <30% empty.
  • Aggregates. SEC-MALS (Wyatt Technology DAWN miniDAWN), DLS.
  • Residual host-cell DNA. qPCR; specification typically <10 ng / 10¹³ vg.
  • Residual host-cell protein (HCP). ELISA (Cygnus Technologies HEK293 HCP); specification <100 ppm.
  • Residual plasmid. qPCR targeting kanR / ampR / E1A.
  • Bioburden, sterility, endotoxin. USP <85> LAL test.
  • Potency. Cell-based functional assay (transduction of target cell line + transgene readout) — drug-specific; FDA requires demonstration linking potency to clinical efficacy.

mRNA CQAs

  • mRNA integrity. Capillary gel electrophoresis (Agilent Fragment Analyzer, Bioanalyzer 6000 RNA Pico) — % full-length.
  • dsRNA contamination. ELISA with J2 antibody (Scicons, EnQuireBio); specification <1 ng/µg mRNA — dsRNA triggers RIG-I/MDA5 IFN response.
  • 5’ capping efficiency. LC-MS (intact-mass or RNase H + LC-MS) — % Cap1 vs Cap0 vs uncapped.
  • PolyA length distribution. Capillary electrophoresis or LC-MS.
  • LNP particle size + PDI. DLS (Malvern Zetasizer); specification 80-100 nm, PDI <0.2.
  • mRNA encapsulation efficiency. Ribogreen (Thermo R11491) — quantifies free vs encapsulated mRNA; specification >90%.
  • Zeta potential. Surface charge.

Regulatory pathway summary

  • FDA OTP (CBER). Pre-IND meeting → IND → Phase 1/2/3 → BLA. RMAT designation (Regenerative Medicine Advanced Therapy; 21st Century Cures Act 2016) for cell + gene therapies — equivalent to fast track + breakthrough but for cell/gene specifically. Accelerated approval if surrogate endpoint reasonably predicts clinical benefit (Elevidys micro-dystrophin expression).
  • EMA ATMP (Advanced Therapy Medicinal Product). Centralized procedure; CAT scientific opinion → CHMP positive opinion → European Commission marketing authorization. PRIME designation accelerates.
  • PMDA (Japan). Sakigake (forerunner) designation; conditional approval pathway for regenerative medicine since 2014.
  • China NMPA. Breakthrough designation; conditional approval.

Long-term follow-up

FDA Guidance (2020) on long-term follow-up of cell + gene therapy products — 5 to 15 years monitoring for integration-related malignancies, persistent transgene expression, immunogenicity, and delayed efficacy.

Off-target and immunogenicity considerations

AAV pre-existing immunity

Neutralizing antibodies (NAbs) against AAV capsid eliminate ~30-70% of patients (varies by serotype). Screening assays: neutralization (cell-based transduction inhibition), total IgG (ELISA). Mitigation: capsid engineering (above), plasmapheresis pre-dose, immunosuppression (rituximab + sirolimus + IVIg — Spark/Roche pediatric hemophilia trial); empty-capsid decoys; IdeS (imlifidase, Hansa Biopharma — IgG-cleaving enzyme used in transplantation; pre-AAV NAb removal in clinical trial).

Lentivirus integration site characterization

LAM-PCR + Illumina sequencing post-treatment identifies integration sites; cluster analysis detects oncogene-proximal hot spots. Routine in ex vivo CAR-T and HSC-LV trial follow-up.

CRISPR off-target

GUIDE-seq, CIRCLE-seq, CHANGE-seq, DISCOVER-Seq, BLISS — unbiased methods detect bona fide off-target editing sites in genome. CRISPResso2 amplicon-NGS quantifies on-target + suspected off-target. FDA requires comprehensive characterization.

Innate immune activation by mRNA

m1Ψ-modified mRNA largely evades TLR3/7/8 + RIG-I; residual activation drives the post-vaccination “reactogenicity” (fever, arthralgia, fatigue). dsRNA contamination is the principal residual activator — eliminated by HPLC cellulose chromatography (Karikó-Buckstein 2011 Nucleic Acids Res).

Aptamers, anticalins, and emerging modalities

Aptamers

Short ssDNA/RNA oligonucleotides folded into 3D shape that binds protein targets. Selected from random libraries via SELEX (Systematic Evolution of Ligands by EXponential enrichment; Tuerk-Gold 1990, Ellington-Szostak 1990).

  • Macugen (pegaptanib; Eyetech / Pfizer). FDA 17 Dec 2004. First approved aptamer. Anti-VEGF RNA aptamer for nAMD. Withdrawn 2017 (commercially obsolete vs Lucentis / Eylea).
  • ARC1779, AS1411, NU172. Multiple aptamer programs paused.

The SomaScan platform (SomaLogic) repurposes SOMAmer aptamers for proteomic measurement rather than therapy — see proteomics-and-mass-spec-deep.

Decoy oligonucleotides

Short dsDNA carrying TF binding consensus → sequester TF and suppress downstream gene activation. NF-κB decoy in clinical trial for atopic dermatitis.

Synthetic mRNA editing tools

Engineered base-editor mRNAs delivered via LNP (Verve VERVE-101) combine mRNA delivery with editing payload — increasingly the dominant in vivo CRISPR architecture.

Targeted protein degradation by RNA

ROSE (RNA-based proteolysis-targeting chimera) — designed RNA aptamer + E3 ligase recruiter. Early academic stage 2024-2026.

Selected leading research groups (2024-2026)

  • Katalin Karikó, Drew Weissman (UPenn → BioNTech/Penn). mRNA platform; Nobel Medicine 2023.
  • Pieter Cullis (UBC). Ionizable lipid + LNP architecture; Onpattro/Pfizer lineage.
  • Daniel Anderson (MIT). Targeted LNP, in vivo CRISPR delivery, SORT (selective organ targeting).
  • Robert Langer (MIT). Drug delivery pioneer; Moderna co-founder; numerous LNP innovations.
  • Norbert Pardi (UPenn). mRNA vaccine immunology.
  • Stephen Quake (Stanford / CZI). Single-molecule + cell-free DNA + mRNA technologies.
  • David Liu (Broad). Base editors, prime editors; Verve / Beam / Prime Medicine co-founder.
  • Feng Zhang (Broad). Cas9 + Cas12 + Cas13 discovery; Editas / Arbor / Sherlock co-founder.
  • Jennifer Doudna (Berkeley). CRISPR fundamentals; IGI clinical translation.
  • Mark Kay (Stanford). AAV gene therapy hemophilia + liver.
  • Jude Samulski (UNC; founder AskBio → Bayer). AAV capsid engineering.
  • James Wilson (UPenn Penn Vector Core). AAV serotype discovery (8, 9, rh10).
  • Alnylam founders (Phil Sharp MIT, Dave Bartel MIT, John Maraganore). siRNA chemistry + GalNAc.
  • Stanley Crooke (Ionis). ASO chemistry; 30+ years; founded Ionis.
  • Sarepta team (Doug Ingram, Louise Rodino-Klapac). Exon-skipping PMO + DMD AAV.
  • Joseph Wu (Stanford). iPSC-derived cardiomyocytes for gene therapy + screening.
  • Akiko Iwasaki (Yale). mRNA vaccine immunology; intranasal RNA vaccines.

Outlook 2026-2030

  • In vivo CRISPR scales beyond liver. Lung (cystic fibrosis), CNS (neurodegeneration), eye, immune cells, heart — capsid + LNP engineering and ML-guided capsid design enabling new tissues.
  • Multi-target / combinatorial editing. Beam BEAM-301 (multiplex base edits in autoimmune T cell), Caribou multi-edit allogeneic CAR-T.
  • Cancer mRNA vaccines expand. Moderna + Merck individualized neoantigen platform (KEYNOTE-942 → INTerpath Phase 3 melanoma + lung + RCC) commercially launched ~2027.
  • mRNA-encoded therapeutic proteins. Replacing recombinant protein for systemic enzyme replacement (Moderna PA, MMA, GSD1a programs).
  • AAV re-dosing. Capsid evolution + transient immunosuppression enabling repeat dosing.
  • Pricing reform. CMS Cell + Gene Therapy Access Model 2025-2030; outcome-based contracts standardize; pricing reform initiatives (NICE-style HTA in US emerging).
  • Off-the-shelf cell therapy. Allogeneic CAR-T (CTX112, ALLO-501A) achieves auto-CAR comparable efficacy at $10-30k COGS.

Adjacent

Further reading

  • Naldini, L. — “Gene therapy returns to centre stage” Nature 2015, 526:351.
  • High, K.A., Roncarolo, M.G. — “Gene Therapy” N Engl J Med 2019, 381:455.
  • Anzalone, A.V., Koblan, L.W., Liu, D.R. — “Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors” Nat Biotechnol 2020, 38:824.
  • Doudna, J.A. — “The promise and challenge of therapeutic genome editing” Nature 2020, 578:229.
  • Hou, X., Zaks, T., Langer, R., Dong, Y. — “Lipid nanoparticles for mRNA delivery” Nat Rev Mater 2021, 6:1078.
  • Karikó, K., Buckstein, M., Ni, H., Weissman, D. — “Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA” Immunity 2005, 23:165.
  • Frangoul, H., et al. — “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia” N Engl J Med 2021, 384:252 — Casgevy / exa-cel pivotal.
  • Gillmore, J.D., et al. — “CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis” N Engl J Med 2021, 385:493 — NTLA-2001 first-in-human in vivo CRISPR.
  • Lee, R.G., et al. — “In vivo PCSK9 base editing reduces low-density lipoprotein cholesterol in non-human primates” Circulation 2023, 147:242 — VERVE-101 NHP data.
  • Sahin, U., Karikó, K., Türeci, Ö. — “mRNA-based therapeutics — developing a new class of drugs” Nat Rev Drug Discov 2014, 13:759.
  • Crooke, S.T., Witztum, J.L., Bennett, C.F., Baker, B.F. — “RNA-Targeted Therapeutics” Cell Metab 2018, 27:714.
  • Alberts, B., Hopkin, K., Johnson, A., et al. — Molecular Biology of the Cell 7th ed., WW Norton 2022 — gene expression and therapy chapters.
  • Stryer, L., Berg, J.M., Tymoczko, J.L., Gatto, G.J. — Biochemistry 9th ed., WH Freeman 2019 — nucleic acid chemistry.
  • Murray, P.R., Rosenthal, K.S., Pfaller, M.A. — Medical Microbiology 9th ed., Elsevier 2021 — viral vector biology background.

Graph View